Grail, Inc. (NASDAQ:GRAL - Get Free Report)'s share price traded up 6.1% during mid-day trading on Wednesday . The stock traded as high as $26.10 and last traded at $26.63. 322,459 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 1,213,854 shares. The stock had previously closed at $25.10.
Wall Street Analyst Weigh In
Separately, Morgan Stanley lifted their price objective on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, March 18th.
Check Out Our Latest Analysis on Grail
Grail Stock Performance
The stock has a fifty day simple moving average of $34.24 and a 200-day simple moving average of $22.86.
Grail (NASDAQ:GRAL - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The firm had revenue of $38.25 million during the quarter, compared to analyst estimates of $35.33 million. On average, equities analysts forecast that Grail, Inc. will post -15.15 earnings per share for the current year.
Insider Buying and Selling
In related news, President Joshua J. Ofman sold 2,109 shares of Grail stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the sale, the president now owns 559,673 shares of the company's stock, valued at approximately $17,461,797.60. The trade was a 0.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the transaction, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at $10,457,304. This trade represents a 0.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,550 shares of company stock worth $360,436.
Institutional Trading of Grail
A number of large investors have recently added to or reduced their stakes in GRAL. Crcm LP bought a new stake in shares of Grail in the 4th quarter valued at about $65,061,000. Sessa Capital IM L.P. acquired a new stake in shares of Grail in the fourth quarter valued at approximately $53,550,000. Primecap Management Co. CA bought a new position in shares of Grail during the 4th quarter worth approximately $37,118,000. Baker BROS. Advisors LP bought a new stake in Grail in the 4th quarter valued at $29,098,000. Finally, Vanguard Group Inc. acquired a new stake in Grail during the 4th quarter valued at $25,902,000.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
